Questions about the safe handling of infectious agents in research settings are popping up on several fronts in the United States and United Kingdom (U.K), reviving a longstanding and highly fragmented debate over where and how to investigate such agents and what safeguards are adequate. In practical terms, elements of this debate tend to take shape locally but can exert widespread effects throughout the community, with far-away incidents or accidents threatening the freedom of microbiologists or other investigators whose laboratory safety records remain untainted. One important general message is "pay close attention," because what now is under review in Congress and in the Supreme Judicial Court of Massachusetts, as well as recent events in labs or on farms in Texas, Wisconsin, or the United Kingdom, could have ripple effects on research freedom throughout the system.
Members of Congress are jumping into this debate, renewing concerns about biosafety that could lead to new restrictions being imposed on laboratories. Early in October, Representatives John D. Dingell (D-MI), who chairs the House Committee on Energy and Commerce, and Bart Stupak (D-MI), who chairs the House Subcommittee on Oversight and Investigations, convened a hearing on biosafety level (BSL) 3 and 4 laboratories. Referring to "a surge in construction of biosafety labs," Dingell says that he is seeking "information about the number of labs being operated in the U.S. and whether they are safely run."
Although he considers research being done in such labs "valuable," he says that steps are needed to "make sure that it does not pose a risk to the public health." As part of this information-gathering effort, the committee asked the Government Accountability Office (GAO) to review these issues, including "whether these biosafety labs are being designed, constructed, and operated safely," Stupak says.
Similar questions were aired last August before the Massachusetts Supreme Judicial Court over the safety of a specific high-containment biosafety research facility being built on part of the Boston University (BU) Medical School campus. The arguments brought before that court stem from a lawsuit filed by a citizen's group against the university and its affiliates early in 2005. The group, "Ten Residents of Boston," asserts that environmental assessments about the safety of the proposed BSL-4 facility were inadequate, that it poses a public health risk to the surrounding community, including through terrorism, accidents, or thefts, and that the university should have considered building the facility at an alternative, less-densely populated site. The Council for Responsible Genetics, which is based in nearby Cambridge, Mass., filed an amicus brief supporting the views of that local citizen's group.
Meanwhile, several professional organizations, including ASM and the Infectious Diseases Society of America, filed amicus briefs supporting plans to build and operate the BSL 4 research facility. "The amicus brief speaks to the issue of [high-containment] labs in general which provide a safe working environment, and the issues of biosafety-rather than one particular situation or another," says Ruth Berkelman of Emory University in Atlanta, Ga., who chairs the ASM Public and Scientific Affairs Board (PSAB). "Such labs are important in the history of public health, and there was a clear consensus among the leaders of ASM, including chairs of several committees, that we should file this brief to underscore the value of these containment labs for research, public health, and the mission of ASM. The issue is not to shut down labs but to make them safe and to minimize human errors."
The Massachusetts court sought amicus briefs earlier this year, leading the PSAB to consult with ASM officers and other leaders over whether to prepare such document, Berkelman says. ASM had done so on several earlier occasions, notably in 1980 to support the case for patenting genetically modified microorganisms in "Diamond v. Chakrabarty" then before the U.S. Supreme Court. As with that earlier case, ASM framed its amicus position not so much on the specifics as on the general principles at stake. In the current case involving the BU BSL-4 research facility, the ASM brief is intended to "educate the public and the court about why these research facilities are needed, particularly because of the emergence of infectious disease agents over recent years," she says. The brief also describes safety features of BSL-4 labs.
"We are seeing biosafety issues in the forefront, and biosafety practices are needed to protect lab workers and the community," Berkelman continues, alluding to several recent inci-dents involving infectious agents at U.S. Researchers have searched for the rate-limiting process in RNAP for a long time, according to microbiologist Artsimovitch. "It took crystallography to show that the 'trigger loop' can refold into helices and close the RNAP active site," she says. "We knew the region was important, but we couldn't predict its dynamics from anything we knew before."
Arsimovitch and her collaborators observed that "trigger loop" within the elongation complex of RNAP, which was purified from Thermus thermophilus, a thermophilic gramnegative bacterium. Isolated RNAP was mixed with RNA and DNA fragments to generate and crystalize three different forms of elongation complex. Subsequent X-ray analysis
Virus Is Likely Culprit for Bee Colony Collapse Disorder
The Israeli Acute Paralysis Virus (IVAP) is a "marker for" and appears a plausible culprit for helping to cause honeybee colony collapse disorder (CCD), according to entomologist Diana CoxFoster of Pennsylvania State University, W. Ian Lipkin of Columbia University in New York, N.Y., and their collaborators there and at the U.S. Department of Agriculture facilities in Beltsville, Md. The investigators used high-throughput DNA sequencing techniques to analyze genetic material from 4 geographic regions and then to identify which among the 6 symbiotic types of bacteria from 8 bacterial groups, 81 fungi, and 7 viruses was most often associated with those bees that experienced CCD. This disorder, which affected nearly one-fourth of U.S. beekeeping operations in 2006 -2007, leaves hives with only a few newly hatched adults, a queen, and food; bees will not recolonize such a hive unless it is irradiated. Details of the study appear in the 6 September online version of Science. showed that the trigger loop folds each time the complex adds a nucleotide to extend a growing messenger RNA chain, and then unfolds as the next cycle begins.
This repetitive closing and opening of the trigger loop "is an essential part of RNA polymerase's catalytic mechanism, and any bacteria would die without this element," Artsimovitch says. Crystallography further reveals that the antibiotic streptolydigin prevents the trigger loop from fully folding. Instead, RNAP becomes hung up, and the elongation cycle stops. Details are published in two papers in the 12 July 2007 Nature (448:157-162, 163-168) .
Although streptolydigin is not used clinically, its capacity to block RNAP by binding to the trigger loop makes this structure a focal point for developing structure-based derivatives that could prove more potent, according to Artsimovitch and her collaborators. The loop sequence in mammalian versions of RNAP differs considerably from those in bacteria, another encouraging sign that novel antimicrobial agents that target this structure would spare RNAP in humans and other mammals. This analysis of RNAP structure "is an important landmark in understanding the molecular basis of transcription," says Jeffrey Roberts, a molecular biologist at Cornell University in Ithaca, New York. In addition to being "good science" that persuasively describes how the active site of RNAP operates, he adds, the results suggest new experiments, including a rationale for drug design.
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Congo Dye Derivatives Free Proteosome To Rid Cells of Prions
Congo red dye, which binds prion proteins, is used widely to detect them in mammalian brains. This property led David Brown of the University of Bath, United Kingdom (U.K.), and his collaborators to develop less-toxic dye derivatives that could target and eliminate prions without poisoning the cells in which those misfolded proteins are found. Although some of those derivatives proved highly effective in cell cultures, their target unexpectedly is the proteosome, Brown and his collaborators report in the October Journal of Virology (81:10729 -10741). The Bath researchers depend on a cell culture model of transmissible spongiform encephalopathies (TSEs) to study prions, which are believed to instigate TSEs in the central nervous system (CNS). As TSEs develop, misfolded prion proteins-notably, the isoform called PrPSc-build up in CNS tissues. However, these same proteins, when properly folded, have neuroprotective effects, Brown says. Prion disease is thought to spread when misfolded prions contact and disrupt properly folded counterpart prions. Brown, like other researchers studying these puzzling proteins, surmised that prion-binding compounds might be used to halt the progress of TSEs by keeping misfolded prions from rearranging their normal counterparts.
Earlier, Brown collaborated with medicinal chemist Ian H. Gilbert of the University of Cardiff in Wales, U.K., to develop less-toxic derivatives of Congo red that would still bind prions. At least one of those derivatives not only cleared cells of misfolded prions, but also blocked further misfolding of properly folded prions and kept derivative-treated (but not
Other Happenings on the Viral Front
Here are some recent noteworthy developments involving viruses:
• Blue-ear pig disease, more formally known as porcine reproductive and respiratory syndrome, widely affected pigs in China and Vietnam this year, but outbreaks are coming under control, officials report.
• The Marburg virus infects African fruit bats (Rousettus aegyptiacus) in the wild, reinforcing suspicions that bats are a likely reservoir (see Microbe, September 2007, p. 418) for this deadly-to-humans virus, according to researchers at the Centers for Disease Control and Prevention in Atlanta, Ga., and their collaborators.
• In tissue cultures, the human adenovirus-36 can transform adult stem cells from obese patients into fat cells, according to Magdalena Pasarica, Nikhil Dhurandhar, and their collaborators from Pennington Biomedical Research Center at Louisiana State University in Baton Rouge, who reported their findings in August at the American Chemical Society meeting in Boston, Mass. Moreover, the E4Orfl gene of this virus appears to be involved in fat accumulation, based on studies of infected animals.
• A single change to a critical lysine residue of the polymerase of poliovirus, a positive-strand RNA virus, can slow and undercut the accuracy of replication enough to make this virus (and perhaps other similar viruses) more readily susceptible than usual to immune system responses, according to Craig Cameron and his collaborators at Pennsylvania State University in University Park. untreated) cells from producing TSE when they were injected into the brains of mice. Thus, Brown says, "One of the derivative compounds really did cure the cells."
To investigate how the Congo red derivatives work at the molecular level, Brown and his collaborators compared the binding properties of several dye derivatives. Unexpectedly, he says, "There was not much difference [in binding] between the compounds that were effective at curing cells and the ones that were not." The surprising reason is that the derivatives act on a downstream target of prions-namely, the proteosomes, which are large protein-containing complexes in cells that degrade proteins that are misfolded or otherwise worn or damaged.
In so doing, Brown and his collaborators uncovered an important fact about how prions disrupt cells. "In other words, prion infection eliminates the proteosome's ability to destroy prions," he says. "In the presence of the Congo red derivatives, this inhibition was reversed." More generally, he predicts, "Finding a cure for prion disease will involve allowing the body's own defenses against misfolded proteins-that is, the proteosome-to do its job." "Treatments of prion diseases based on cell models are notoriously unreliable," cautions Pierluigi Gambetti of Case Western Reserve University in Cleveland, Ohio. Nonetheless, he adds, identifying derivatives that unleash proteosome activity is "of considerable practical importance." One unusual possibility from their findings is that lateral gene transfers from ancient microorganisms could occur periodically when intermittent global warming allowed glacial meltwaters to carry their DNA molecules into other species dwelling in the sea. "What we are saying is that there could be a release of some ancient genes from melting glaciers that drain into the oceans where microorganisms living in the sea obtain those traits," Bidle says. "This could be one mechanism by which evolution can happen on a potentially large, rapid scale, and it can be tied to climate change." Bidle, Marchant, and their collaborators obtained two separate ice-core samples containing trapped debris, both from the Mullins Valley region of Antarctica. One, called DLE-98 -12, was extracted from an alpine glacier and has an estimated age of 100,000 years. The second sample, EME-98 -03, is much older, perhaps 8 -10 million years old. Marchant determined the ages of the ice samples using a combination of To analyze DNA from any microorganisms within the ice samples, Bidle and his collaborators used bacteriaspecific 16S rDNA primers to amplify community DNA to make clone libraries. Similar analyses using archaeon-and eukaryote-specific primers proved negative. Both ice samples show only a few bacterial phylotypes. The younger sample, DLE-98 -12, has a 98% match to Leptothrix sp., while the older sample, EME-98 -03, is dominated by one phylotype, B-proteobacteria and, to Bidle's surprise, also contains genes "whose closest match was Deinococcus radiodurans, a microbe that has exceptional DNA repair ability," he says.
David Holzman
To see whether the bacteria from the ice cores are viable, Bidle's team C-glucose to look for any metabolic gases coming from microorganisms. The response from EME-98 -03 was significantly diminished compared to that of DLE-98 -12 due to the extended time the bacteria in the older sample spent encased in ice, according to Bidle.
Whether the bacteria were fully dormant or had been slowly metabolizing while entrapped in ice is uncertain. "Based on the results of our geochemical and ice structure data, there wasn't any melting or water formation in the glacier, but in other studies with Lake Vostok ice core samples, others have shown that you can get small microlayers around mineral particles that might provide a microenvironment in which bacteria could remain slowly active," Bilde says. The researchers rule out contamination, arguing that isotopic data show no evidence of meltwater or of melt holes during their entire residence in Antarctica, making it the oldest ice found on Earth so far. How the DNA remained intact in 8-million-year-old bacteria is not known, but Bidle says that a repair mechanism similar to what Deinococcus radiodurans relies on to repair radiation damage might help to explain what they found.
One of the most important findings is the difference in degree of damage to DNA in the 8-million-year-old sample compared to the 100,000-year-old sample. "The large influx of cosmic radiation at the Arctic and Antarctic exponentially limits the time in which DNA could contain functional information," Bidle says. "We estimate a half-life of 1.1 million years." From the study, Bidle and his collaborators place a time constraint on the idea that comets could seed the universe with life, a theory known as panspermia.
Since comets are considered "dirty snowballs," and these ice-core samples were from a buried glacier that had not been exposed to the atmosphere, the researchers drew an analogy to a comet. "Since cosmic radiation is much higher in space than it is in Antarctica and given it would take a comet traveling from one solar system to another much longer than 8 million years to get there, we think it is unlikely that you would have any functional DNA of any considerable size, let alone any intact microorganisms," Bidle notes.
"Survival for 1.1 million years in a dilute cosmic radiation field is more than enough for panspermia to work, and the authors show survivors for 8 million years," says Chandra Wickramasinghe, Director of the Cardiff Centre for Astrobiology in Wales, United Kingdom, who is the leading proponent of the panspermia theory. "In the panspermia models we are working on, expulsion from the secure interior of a comet to interplanetary space and to reach the secure environment in the interior of a nearby nascent planetary/cometary system is less than a couple of million years." Three distinct sets of lethal antibiotics kill bacterial cells through a common "downstream" mechanism involving active oxygen species, namely hydroxyl radicals, according to James Collins of Boston University in Boston, Mass., and his collaborators. Although the three types of cidal antibiotics separately affect either DNA, protein, or cell wall synthesis, the immediate damages that they cause trigger a common cell-death response, the researchers report. This response involves several metabolic components of bacterial cells, including the tricarboxylic acid cycle, transiently depleting the cofactor nicotine adenine dinucleotide (NADH), destabilizing iron-sulfur clusters, and stimulating the Fenton reaction, in which iron ions react with molecules of hydrogen peroxide to yield hydroxyl radicals. Details appear in the 7 September 2007 issue of Cell (130:797-810) . are linked to some other chemical moiety-hence, the "x" in the family name, Nudix.
"We have been systematically isolating these genes, cloning them, expressing them in E. coli, purifying the proteins, and identifying their functions," Bessman says. In particular, they had characterized 12 of 13 Nudix hydrolases whose genes are found along the E. coli genome. However, the 13th proved elusive. To supplement recent genomics data, Bessman searched the literature for metabolic pathways involving nucleoside diphosphates, and learned from a report published more than 30 years ago that an E. coli enzyme involved in folate synthesis has what appeared to be the biochemical characteristics of a Nudix hydrolase. Thus, its substrate, dihydroneopterin triphosphate and the reaction being catalyzed are typical of what Nudix hydrolases do.
Despite these promising clues from that 1974 report, however, the 13th E. coli Nudix hydrolase failed to hydrolyze dihydroneopterin triphosphate, the relevant substrate of the folate biosynthetic pathway. Frustrated, they tested the other 12 Nudix enzymes from E. coli. One of them, which hydrolyzes dATP, proves far more catalytically active when supplied with dihydroneopterin triphosphate. The researchers now believe that this enzyme, and not the stilluncharacterized 13th Nudix hydrolase from E. coli, is the hydrolase of the folate synthetic pathways.
They back this surmise from the enzyme reaction rate measurements with gene knockout experiments, in which folate synthesis is reduced by about 10-fold, according to Bessman. Although residual folate biosynthesis is enough to maintain normal growth rates in knockout mutants, those mutations render E. coli "extremely sensitive to sulfa drugs," he says. Nonetheless, these physiological findings could mean that this enzyme's potential as a target for antimicrobial agents is limited, according to Alexander G. McLennan of the University of Liverpool in the United Kingdom, whose commentary on the Nudix hydrolase findings appears in the same issue of Structure.
In more general terms, the folate biosynthetic pathway in bacteria makes a good target for the sulfonamide antibiotics because it has no direct counterpart in humans. Moreover, this enzyme's critical role as a "committing step" for metabolites moving into and through this biosynthetic pathway makes it appear a particularly good candidate target.
"Committing steps are good, and rate-limiting steps are better and not always the same as targets," says Lynn Silver of Springfield, N.J., who is a consultant specializing in antibacterial discovery. Chemotherapy to block this or other metabolic pathways that relies on using two single-target inhibitors concurrently might reduce the potential for resistance, she says. It is also likely that such agents would act synergistically, she adds.

UNICEF Reports Global Lowering of Deaths among Children
Deaths among children under 5 years of age fell below the 10 million threshold for the first time worldwide, signifying major progress since 1990 when such deaths reached nearly 13 million, according to officials at UNICEF in New York, N.Y. The Latin American and Caribbean region is helping to lead this trend by now reporting only 27 deaths on average for every 1,000 live births, compared to 55 per 1,000 in 1990. Much of this progress is attributed to widespread adoption of public health interventions such as breast feeding, measles immunization, usage of insecticide-treated bed nets to prevent malaria, and taking vitamin A supplements. However, West and Central African countries continue to experience the highest rates of child mortality, while HIV and AIDS undermine progress throughout much of Africa, particularly in the south.
